PHARMACYCLICS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2014-12-11: Form 8-K; Period of report 2014-12-06; Description 8.01 Other Events; Details 8.01.
- 2014-12-02: Form 8-K; Period of report 2014-12-01; Description 8.01 Other Events; Details 8.01.
- 2014-11-28: Form 8-K; Period of report 2014-11-24; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2014-11-12: Form 8-K; Period of report 2014-11-04; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2014-12-11 | 8-K | 2014-12-06 | 8.01 Other Events | 8.01 · On December 5, 2014, the Company announced the launch of informCLL™, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (“CLL”), examine how IMBRUVICA® and other approved targeted therapies are being used to treat patients with CLL, and provide a comparison to treatments using conventional chemoimmunotherapy. | form8k07380004a_12092014.htm |
| 2014-12-02 | 8-K | 2014-12-01 | 8.01 Other Events | 8.01 On December 1, 2014, Pharmacyclics, Inc. (the “Company”) earned a $20 million milestone payment under its collaboration agreement with Janssen Biotech Inc. as a result of the European Medicines Agency (“EMA”) accepting a Type II variation application (the “Application”) for IMBRUVICA® (ibrutinib). | form8k07380004_12012014.htm |
| 2014-11-28 | 8-K | 2014-11-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 The Compensation Committee of the Board of Directors of Pharmacyclics, Inc. (the “Company”) approved base salary increases, effective as of November 24, 2014, for the following officers: Mahkam Zanganeh, D.D.S., MBA, the Company's Chief Operating Officer, from $489,600 to $705,000, Manmeet Soni, the Company’s Chief Financial Officer, from $408,000 to $580,000 and Heow Tan, the Company’s Chief of Quality and Technical Operations, from $387,600 to $410,000. | form8k07380004_11242014.htm |
| 2014-11-12 | 8-K | 2014-11-04 | 7.01 Regulation FD Disclosure | 7.01 On November 4, 2014, Pharmacyclics, Inc. (the “Company”) held its quarterly earnings call (the “Earnings Call”) to discuss the financial results from its third quarter ended September 30, 2014. | form8k07380004b_11042014.htm |
| 2014-11-06 | 8-K | 2014-11-06 | 7.01 Regulation FD Disclosure | 7.01 At the American Society of Hematology’s (“ASH”) 56th Annual Meeting located in San Francisco, California from December 6 through 9, 2014, eight (8) abstracts with respect to Pharmacyclics, Inc.’s (the “Company”) product, IMBRUVICA® (ibrutinib), were accepted for oral presentation. | form8k07380004_11062014.htm |
| 2014-11-06 | 8-K | 2014-11-06 | 8.01 Other Events | 8.01 On November 6, 2014, Pharmacyclics, Inc., a Delaware corporation (the “Company”), issued a press release announcing broad array of new IMBRUVICA® (ibrutinib) data across multiple histologies will be presented at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco, CA from December 6 - 9, 2014. | form8k07380004b_11062014.htm |
| 2014-11-04 | 8-K | 2014-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 On November 4, 2014, Pharmacyclics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the third quarter ended September 30, 2014. | form8k07380004_11042014.htm |
| 2014-10-20 | 8-K | 2014-10-17 | 8.01 Other Events | 8.01 On October 17, 2014, Pharmacyclics, Inc. (the “Company”) earned an $80 million milestone payment under its collaboration agreement with Janssen Biotech Inc. as a result of the European Commission (“EC”) granting marketing approval for IMBRUVICA® (ibrutinib) throughout the 28 member states of the European Union (“EU”). | pharmacyclics8k_oct172014.htm |
| 2014-09-30 | 8-K | 2014-09-24 | 1.02 Termination of a Material Definitive Agreement; 8.01 Other Events | 1.02 On September 25, 2014, Les Laboratoires Servier and Institut de Recherches Internationales Servier (collectively, “Servier”) and Pharmacyclics, Inc. (the “Company”) announced that they have mutually and amicably ended their collaboration pertaining to the ex-U.S. development of the Company’s pan-HDAC inhibitor compounds, including abexinostat, thereby returning global development and commercialization rights to the Company. 8.01 A copy of the press release announcing the termination of the collaboration is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | form8k07380004_09242014.htm |
| 2014-08-29 | 8-K | 2014-08-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 25, 2014, the Compensation Committee of the Board of Directors of Pharmacyclics, Inc. (the “Company”) approved 2014 mid-year cash bonuses for certain officers of the Company, including $151,742 for Mahkam Zanganeh, the Company’s Chief Operating Officer, $126,452 for Manmeet Soni, the Company’s Chief Financial Officer, and $105,714 for Heow Tan, the Company’s Chief of Quality and Technical Operations. | form8k07380004_08252014.htm |
| 2014-08-14 | 8-K/A | 2013-11-13 | 9.01 Financial Statements and Exhibits | 9.01 Exhibit No. Description 10.1* Manufacturing Supply Agreement, dated February 5, 2013, between Pharmacyclics, Inc. and Lonza Sales Ltd. 10.2* Amendment No. 1 to Manufacturing Supply Agreement, dated October 2, 2013, between Pharmacyclics, Inc. and Lonza Sales Ltd. 10.3* Build Out and Commercial Supply Agreement, dated May 1, 2013, between Pharmacyclics, Inc. and Catalent CTS, LLC. | form8ka07380004_11132013.htm |
| 2014-08-08 | 8-K | 2014-08-07 | 8.01 Other Events | 8.01 Pharmacyclics, Inc. (the “Company”) announced the transition of Dr. Jesse McGreivy from his current position of Chief Medical Officer to that of a senior advisor to the Company. | pharmacyclics8kaug72014.htm |
| 2014-08-04 | 8-K | 2014-07-31 | 7.01 Regulation FD Disclosure | 7.01 On July 31, 2014, Pharmacyclics, Inc. (the “Company”) held its quarterly earnings call (the “Earnings Call”) to discuss the financial results from its second quarter ended June 30, 2014. | form8k07380004b_07312014.htm |
| 2014-07-31 | 8-K | 2014-07-31 | 2.02 Results of Operations and Financial Condition | 2.02 On July 31, 2014, Pharmacyclics, Inc., a Delaware corporation (the “Registrant”), issued a press release regarding its financial results for its second quarter ended June 30, 2014. | form8k07380004_07312014.htm |
| 2014-07-31 | 8-K | 2014-07-28 | 7.01 Regulation FD Disclosure | 7.01 On July 28, 2014, Pharmacyclics, Inc. (the “Company”) issued a press release and hosted a conference call to discuss the Company’s announcement that the U.S. Food and Drug Administration has granted IMBRUVICA® (ibrutinib) regular (full) approval for the treatment of patients with chronic lymphocytic leukemia (“CLL”) who have received at least one prior therapy, and for the treatment of CLL patients with deletion of the short arm of chromosome 17 (“del 17p CLL”), including treatment naive and previously treated del 17p CLL patients. | form8k07380004_07282014.htm |
| 2014-06-05 | 8-K | 2014-06-03 | 7.01 Regulation FD Disclosure | form8k07380_05312014.htm | |
| 2014-05-23 | 8-K | 2014-05-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective May 20, 2014, Paula Boultbee, a named executive officer of Pharmacyclics, Inc. (the “Company”), resigned as an employee of the Company. | form8k07380004_05202014.htm |
| 2014-05-16 | 8-K | 2014-05-14 | 7.01 Regulation FD Disclosure | 7.01 On May 14, 2014, Pharmacyclics, Inc., a Delaware corporation (the “Company”), announced that IMBRUVICA® (ibrutinib) will be featured in ten abstracts, including both company-sponsored research studies and investigator-sponsored studies, at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 30 through June 3, 2014, in Chicago, IL (the “2014 ASCO Meeting”). | form8k07380_05152014.htm |
| 2014-05-14 | 8-K | 2014-05-08 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 5.02 On May 9, 2014, the Company adopted a 2014 corporate cash bonus plan applicable to all employees of the Company, including its named and other executive officers, other than the Company’s Principal Executive Officer. 5.07 At the Annual Meeting the following four matters were put forth to the stockholders to be voted on: (1) the election of seven (7) directors to serve until the 2015 annual meeting and until their successors are duly elected and qualified; (2) the approval of the 2014 Plan; (3) a proposal to consider and approve an advisory resolution regarding the compensation of the Company’s named executive officers; and (4) the ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2014. 8.01 On May 9, 2014, upon the recommendation of the Company’s Compensation Committee, the Board of Directors approved an increase in the annual retainer paid to each member of the Board of Directors from $16,000 to $32,000, payable quarterly. | form8k07380_05082014.htm |
| 2014-05-07 | 8-K | 2014-05-02 | 7.01 Regulation FD Disclosure | 7.01 On May 2, 2014, Pharmacyclics, Inc. (the “Company”) held its quarterly earnings call to discuss the financial results from its first quarter ended March 31, 2014. | form8k07380a_05022014.htm |
| 2014-05-02 | 8-K | 2014-05-02 | 2.02 Results of Operations and Financial Condition | 2.02 On May 2, 2014, Pharmacyclics, Inc., a Delaware corporation (the “Registrant”), issued a press release regarding its financial results for its first quarter ended March 31, 2014. | form8k07380_05022014.htm |
| 2014-04-21 | 8-K | 2014-04-21 | 7.01 Regulation FD Disclosure | 7.01 · Oral Presentation: Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial (Abstract #LBA7008); Date: Tuesday, June 3, 2014; Presentation Time: 11:57 AM; Location: McCormick Place, Room E354A; Presenter: John C. Byrd, M.D., The Ohio State University; Session: Leukemia, Myelodysplasia, and Transplantation Oral Abstract Session. | form8k07380_04212014.htm |
| 2014-04-08 | 8-K | 2014-04-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 2, 2014, Pharmacyclics, Inc. (the “Company”) granted options to purchase shares of common stock to certain its officers in the following amounts, including: (i) 40,000 to Mahkam Zanganeh, its Chief Operating Officer, (ii) 40,000 to Manmeet Soni, its Chief Financial Officer and Treasurer, and (iii) 30,000 to Heow Tan, its Chief of Quality and Technical Operations. | form8k07380_04022014.htm |
| 2014-04-08 | 8-K | 2014-04-08 | 8.01 Other Events | 8.01 On April 8, 2014, Pharmacyclics, Inc. (the “Company”) announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA), based on data from the randomized, multi-center, open-label Phase III RESONATETM study, PCYC-1112, a head-to-head comparison of single agent IMBRUVICATM (ibrutinib) versus ofatumumab in 391 patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who had received at least one prior therapy. | form8k07380_04082014.htm |
| 2014-03-27 | 8-K | 2014-03-26 | 8.01 Other Events | 8.01 Pharmacyclics, Inc. (the “Company”) today announced that a former employee filed a complaint against the Company in Superior Court of Santa Clara, California. | form8k07380_03262014.htm |
| 2014-03-04 | 8-K | 2014-03-04 | 8.01 Other Events | 8.01 Pharmacyclics, Inc. (the “Company”) opened its trading window on February 25, 2014, and certain of its directors and executives may sell shares of the Company’s common stock that they hold, and/or exercise options they hold, and sell the shares immediately following exercise. | pcyc8kmar42014.htm |
| 2014-02-25 | 8-K | 2014-02-20 | 7.01 Regulation FD Disclosure | 7.01 On February 20, 2014, Pharmacyclics, Inc. (the “Company”) held its quarterly earnings call to discuss the financial results from its fourth quarter and year ended December 31, 2013. | form8k07380a_02202014.htm |
| 2014-02-20 | 8-K | 2014-02-20 | 2.02 Results of Operations and Financial Condition | 2.02 On February 20, 2014, Pharmacyclics, Inc., a Delaware corporation (the “Registrant”), issued a press release regarding its financial results for its fourth quarter and year ended December 31, 2013. | form8k07380_02202014.htm |
| 2014-02-14 | 8-K | 2014-02-12 | 7.01 Regulation FD Disclosure | 7.01 On February 12, 2014, Pharmacyclics, Inc. (the “Company”) hosted a conference call to discuss the Company’s announcement that the U.S. Food and Drug Administration has approved IMBRUVICA™ (ibrutinib) as a single agent for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy. | form8k07380a_02122014.htm |
| 2014-02-12 | 8-K | 2014-02-12 | 8.01 Other Events | 8.01 On February 12, 2014, Pharmacyclics, Inc. (the “Company”) today announced that the U.S. Food and Drug Administration has approved IMBRUVICA™ (ibrutinib) as a single agent for the treatment of patients with chronic lymphocytic leukemia (“CLL”) who have received at least one prior therapy. | form8k07380_02122014.htm |
| 2014-02-05 | 8-K | 2014-02-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 4, 2014, Manmeet Soni, Pharmacyclics, Inc.’s (the “Company”) Principal Financial Officer, Principal Accounting Officer and Executive Vice President, Finance was promoted to the position of Chief Financial Officer. | form8k07380_02042014.htm |
| 2014-01-13 | 8-K | 2014-01-13 | 7.01 Regulation FD Disclosure | 7.01 On January 13, 2014, Pharmacyclics, Inc. (the “Company”) announced that the National Comprehensive Cancer Network (the “NCCN”) updated its NCCN Clinical Practice Guidelines in Oncology (the “NCCN Guidelines®”) in Non-Hodgkin’s Lymphomas (Version 1.2014) and in Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma (Version 1.2014). | pcyc-8k_011314.htm |
| 2014-01-07 | 8-K | 2014-01-07 | 8.01 Other Events | 8.01 On January 7, 2014, Pharmacyclics, Inc. (the “Company”) announced that the independent Data Monitoring Committee recommended that the Company’s Phase III study of IMRUVICA™ (ibrutinib) versus ofatumumab be stopped early based on statistically significant improvement in progression free survival and overall survival. | form8k07380_01072014.htm |